Shares of Agenus Inc. (NASDAQ:AGEN) traded up 4.7% on Wednesday . The stock traded as high as $5.85 and last traded at $5.81, with a volume of 723,144 shares changing hands. The stock had previously closed at $5.55.

A number of brokerages have commented on AGEN. HC Wainwright reiterated a “buy” rating on shares of Agenus in a research report on Saturday, April 30th. Maxim Group reiterated a “buy” rating on shares of Agenus in a research report on Wednesday, April 27th. Jefferies Group raised their price objective on Agenus from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, July 29th. Finally, Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $10.25.

The stock has a 50-day moving average price of $4.57 and a 200 day moving average price of $3.90. The company’s market capitalization is $499.57 million.

Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, July 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company earned $6.59 million during the quarter, compared to analyst estimates of $5.12 million. Equities analysts predict that Agenus Inc. will post ($1.27) earnings per share for the current year.

In related news, CEO Garo H. Armen bought 100,000 shares of the stock in a transaction that occurred on Monday, May 9th. The shares were acquired at an average price of $3.18 per share, with a total value of $318,000.00. Following the completion of the transaction, the chief executive officer now owns 1,346,026 shares in the company, valued at $4,280,362.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.